Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RGNX vs DMAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Captures Overall Composite Edge (46.3 HOLD vs 45.3 HOLD), While RGNX Leads 4–2 on Growth & Valuation Pillars

DMAC Overall Winner 6-Pillar Tally: RGNX 4 – 2 DMAC Matrix Metrics: RGNX 2 – 5 DMAC

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (46.3/100 HOLD vs. 45.3/100 HOLD) after splitting the core matrix 5–2 (led by Growth & Scale, Profitability & Quality), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. RGNX trades at $7.47 (N/M Forward P/E, -120.4% operating margin) versus DMAC at $8.41 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. RGNX 45.3/100 HOLD) and 1.74β · 98% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RGNX vs DMAC
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.81β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.7 · SMA20: $9.24 · SMA50: $8.24

6-Pillar Scorecard Institutional Category Breakdown (RGNX 4 – 2 DMAC)

Columns: Metric · RGNX · DMAC
1. Valuation Multiples RGNX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio 0.26x N/M
EV / Revenue 3.1x N/M
2. Growth & Scale DMAC
Revenue Growth (YoY) -69.2% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $154M N/A
Market Cap $500.9M $503.1M
3. Profitability & Quality DMAC
Gross Margin -64.5% N/A
Operating Margin -120.4% 0.0%
Net Profit Margin -113.9% 0.0%
Return on Equity (ROE) -113.2% -114.6%
4. Balance Sheet & Cash Flow RGNX
Cash Generation (TTM) -$155M -$32M
Cash Flow Margin -100.6% N/A
Net Cash / Leverage $29M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RGNX
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 349.6% (52nd %ile) 106.3% (14th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity 55.9% of Rev ($86M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RGNX (2) vs DMAC (5)
Institutional Metric RGNX DMAC Criterion Row Edge
Market Capitalization
Scale
$500.9M $503.1M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-69.2% +0.0% Higher Growth DMAC
Operating Margin (TTM)
Profitability
-120.4% 0.0% Higher Margin DMAC
Net Profit Margin
Profitability
-113.9% 0.0% Higher Margin DMAC
Return on Equity (ROE)
Capital Efficiency
-113.2% -114.6% Higher ROE RGNX
52-Week Range Position
Momentum
19% ($5–$16) 55% ($5–$11) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
1.81β · 76% Vol 1.74β · 98% Vol Lower Realized Risk RGNX
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite DMAC
Trailing 12M Revenue (USD)
Operating Scale
$154M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-64.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.26x PEG · 3.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$155M ($29M Net Cash) -$32M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +3.29 pp
RGNX: +7.87% · DMAC: +11.16%
3M Horizon DMAC +59.83 pp
RGNX: -32.52% · DMAC: +27.31%
6M Horizon DMAC +15.94 pp
RGNX: +32.21% · DMAC: +48.15%
1Y Horizon DMAC +91.08 pp
RGNX: -35.82% · DMAC: +55.26%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RGNX Revenue DMAC Revenue RGNX Op. Margin DMAC Op. Margin Margin Leader
FY2018 $220M $0M 40.3% -1352.2% RGNX
FY2019 $40M N/A -422.9% N/A RGNX
FY2020 $150M N/A -77.1% N/A RGNX
FY2021 $470M N/A 34.0% N/A RGNX
FY2022 $110M N/A -233.2% N/A RGNX
FY2023 $90M N/A -297.1% N/A RGNX
FY2024 $80M N/A -280.0% N/A RGNX
FY2025 $170M N/A -94.6% N/A RGNX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RGNX vs DMAC Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (46.3/100 HOLD vs. 45.3/100 HOLD) after splitting the core matrix 5–2 (led by Growth & Scale, Profitability & Quality), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. RGNX trades at $7.47 (N/M Forward P/E, -120.4% operating margin) versus DMAC at $8.41 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. RGNX 45.3/100 HOLD) and 1.74β · 98% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DMAC leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while DMAC shifted N/A. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.

RGNX screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus DMAC (-114.6% ROE) capital efficiency.

In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 76% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.